Is NCT07527299 recruiting in Jonesboro, AR?

Yes, NCT07527299 is currently recruiting participants at its Jonesboro, AR location. This atrial fibrillation clinical trial is actively enrolling qualified participants.

How do I join the atrial fibrillation clinical trial in Jonesboro?

To join this clinical trial in Jonesboro, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Jonesboro clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Atrial Fibrillation Clinical Trial in Jonesboro, AR

About This Atrial Fibrillation Study in Jonesboro

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; PVI and SVCI), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation.

Sponsor: Biosense Webster, Inc.

Who Can Participate

Inclusion Criteria

Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days in duration and less than 365 days in duration, documented by: i. A physician's note documenting diagnosis of symptomatic PsAF, as defined above; and ii. Two electrocardiograms (ECGs) showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than (\>) 365 days prior to enrollment); or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days

Participant is aged 18 - 80 years at the time of informed consent

Participant is willing and capable of providing informed consent

Participant is able and willing to comply with all pre-, post- and follow-up testing and requirement Left atrial appendage occlusion (LAAO) concomitant subset: \- Participant is clinically indicated for a LAAO procedure

Exclusion Criteria

Participant has continuous AF \> 365 days (longstanding persistent AF)

Participant has AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, untreated documented obstructive sleep apnea, acute alcohol toxicity, etc.)

Participant has had previous surgical or catheter ablation for AF

Participant is known to require ablation outside the left atrium (LA), superior vena cava (SVC), and the cavotricuspid isthmus (CTI) region (for example, atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, ventricular tachycardia and Wolff-Parkinson-White)

Participant has severe dilatation of the LA (left atrial diameter \[LAD\] \> 50 millimeters \[mm\]) of the antero-posterior diameter confirmed by imaging performed within 180 days prior to enrollment

Participant has LA thrombus confirmed by imaging within 48 hours prior to the procedure

Participant has severely compromised left ventricular ejection fraction (left ventricle ejection fraction \[LVEF\] less than \[\<\] 40 percent \[%\]) confirmed by imaging performed within 180 days prior to enrollment

Participant has uncontrolled heart failure or New York heart association (NYHA) Class III or IV functional classification

Participant has a history of blood clotting, bleeding abnormalities or contraindication to anticoagulation (for example, heparin)

Participant has had a thromboembolic event (including transient ischemic attack \[TIA\]) within the past 180 days prior to enrollment

Participant has had a percutaneous coronary intervention or acute myocardial infarction (MI) within past 60 days prior to enrollment

Participant has had coronary artery bypass grafting (CABG) surgery within the past 180 days prior to enrollment

Participant has had valvular cardiac surgical/percutaneous procedure (that is, ventriculotomy, atriotomy, valve repair or replacement and presence of a prosthetic valve)

Participant has unstable angina within past 6 months prior to enrollment

Participant has anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 365 days post-procedure

Participant has significant pulmonary disease (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms

Participant has a significant congenital anomaly (for example, atrial septal defects \[ASDs\]) including repaired defects or medical problems that in the opinion of the Investigator would preclude enrollment in this study

Participant has an existing diagnosis of pulmonary vein stenosis (PVS)

Participant has a pre-existing hemi-diaphragmatic paralysis

Participant has an acute illness, active systemic infection, or sepsis

Participant has an intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation

Participant has severe mitral regurgitation (Regurgitant volume greater than or equal to \[\>=\] 60 milliliters \[mL\]/beat, Regurgitant fraction \>= 50%, and/or Effective regurgitant orifice area \>= 0.40 square centimeter \[cm\^2\])

Participant has an implanted metal cardiac device (other than coronary stents, implanted pacemaker, implantable cardioverter-defibrillator \[ICD\], implantable loop recorder \[ILR\]) that may interfere with the pulsed field (PF) energy field

Participant has a condition that precludes vascular access (such as inferior vena cava \[IVC\] filter) - Participant is currently enrolled in an investigational study evaluating another device or drug

Participant is pregnant, lactating, or is of child-bearing potential and plans on trying to become pregnant during the course of the clinical investigation

Participant has a life expectancy of less than 365 days

Participant has contraindications for the devices used in the study, as indicated in the respective instructions for use (IFUs)

Participant has contraindications for the ablation of the SVC LAAO concomitant subset:

Participant is contraindicated for a LAAO procedure per the instructions of use of the planned LAAO device

Participant with prior LAAO procedure (attempted or successful)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Jonesboro?

Yes, this clinical trial (NCT07527299) has an active research site in Jonesboro, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atrial Fibrillation Treatment Options in Jonesboro, AR

If you're searching for atrial fibrillation treatment options in Jonesboro, AR, this clinical trial (NCT07527299) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Jonesboro research site is actively enrolling participants for this clinical trial. You'll receive care from experienced atrial fibrillation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atrial fibrillation clinical trials near you to find additional studies recruiting in your area.

Atrial Fibrillation Clinical Trial in Jonesboro, AR

Expert Care in Jonesboro

IRB Approved

No-Cost Care

Apply for This Jonesboro Location

Why Participate?

Simple Process